AVTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Avalo Therapeutics Inc (AVTX) shows some positive momentum in technical indicators and analyst optimism for its lead program, but the company's financial performance is significantly weak, with no revenue and substantial losses. Given the investor's beginner level, long-term strategy, and impatience for optimal entry points, AVTX is not a strong buy at this time. A hold recommendation is more prudent until clearer financial improvements or catalysts emerge.
The technical indicators suggest a bullish trend with MACD positively expanding, RSI at 74.167 in the neutral zone, and bullish moving averages (SMA_5 > SMA_20 > SMA_200). The stock is trading near resistance levels (R1: 17.27, R2: 18.288), which could limit short-term upside.
Analysts have initiated coverage with high price targets ($39-$
and positive sentiment around the company's lead program AVTX-009, projecting significant future sales.
Hedge funds are heavily buying, with an 829.12% increase in buying activity over the last quarter.
The company's financials are extremely weak, with no revenue, a significant net income loss (-$30.63M), and declining EPS (-22.61% YoY).
No recent news or congress trading data to support immediate positive sentiment.
Post-market price dropped by -1.96%, indicating potential short-term weakness.
In Q3 2025, Avalo Therapeutics reported a 100% YoY revenue decline to $0, a net income loss of -$30.63M (-660.69% YoY), and an EPS drop to -2.19 (-22.61% YoY). Gross margin also dropped to 0, highlighting severe financial challenges.
Analysts are optimistic about AVTX, with Guggenheim and Mizuho initiating coverage with Buy/Outperform ratings and price targets of $50 and $39, respectively. They cite the potential of AVTX-009 as a novel therapeutic with significant sales projections if approved.
